title: Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo.
abstract: The NF-kappaB signaling pathway is known to play an important role in the regulation of osteoclastic bone resorption and cancer cell growth. Previous studies have shown that genetic inactivation of IkappaB kinase (IKK), a key component of NF-kappaB signaling, inhibits osteoclastogenesis, but the effects of pharmacologic IKK inhibitors on osteolytic bone metastasis are unknown. Here, we studied the effects of the IKK inhibitors celastrol, BMS-345541, parthenolide, and wedelolactone on the proliferation and migration of W256 cells in vitro and osteolytic bone destruction in vivo. All compounds tested inhibited the growth and induced apoptosis of W256 cells as evidenced by caspase-3 activation and nuclear morphology. Celastrol, BMS-345541, and parthenolide abolished IL1beta and tumor necrosis factor alpha-induced IkappaB phosphorylation and prevented nuclear translocation of NF-kappaB and DNA binding. Celastrol and parthenolide but not BMS-345541 prevented the activation of both IKKalpha and IKKbeta, and celastrol inhibited IKKalpha/beta activation by preventing the phosphorylation of TAK1, a key receptor-associated factor upstream of IKK. Celastrol and parthenolide markedly reduced the mRNA expression of matrix metalloproteinase 9 and urinary plasminogen activator, and inhibited W256 migration. Administration of celastrol or parthenolide at a dose of 1 mg/kg/day suppressed trabecular bone loss and reduced the number and size of osteolytic bone lesions following W256 injection in rats. Histomorphometric analysis showed that both compounds decreased osteoclast number and inhibited bone resorption. In conclusion, pharmacologic inhibitors of IKK are effective in preventing osteolytic bone metastasis in this model and might represent a promising class of agents to the prevention and treatment of metastatic bone disease associated with breast cancer.
authors: Bone Research Group, Institute of Genetic and Molecular Medicine, University of Edinburgh, General Western Hospital, Edinburgh EH4 2XU, United Kingdom. aymen.idris@ed.ac.uk
authors: Aymen I
authors: AI
authors: Idris
authors: Hélène
authors: H
authors: Libouban
authors: Hervé
authors: H
authors: Nyangoga
authors: Euphemie
authors: E
authors: Landao-Bassonga
authors: Daniel
authors: D
authors: Chappard
authors: Stuart H
authors: SH
authors: Ralston
mesh_terms: D000818:Animals; D017209:Apoptosis; D001859:Bone Neoplasms / Q000517:prevention & control / Q000556:secondary*; D001862:Bone Resorption / Q000378:metabolism / Q000473:pathology; D002279:Carcinoma 256, Walker / Q000201:enzymology / Q000556:secondary*; D002465:Cell Movement / Q000187:drug effects; D005260:Female; D006801:Humans; D051550:I-kappa B Kinase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000201:enzymology / Q000473:pathology*; D010010:Osteoclasts / Q000187:drug effects / Q000473:pathology; D010014:Osteolysis / Q000517:prevention & control*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D047428:Protein Kinase Inhibitors; D051550:I-kappa B Kinase